Symbiotec Pharmalab Limited (symbiotec) Q1fy27: Steady Performance with Revenue Up 6%

Symbiotec Pharmalab Limited (SYMBIOTEC) has delivered steady performance for Q1FY27, showcasing consistent growth in its core API business and promising developments in new growth areas. The company’s operating revenue for the API business increased by 6% year-on-year to Rs. 215.3 crore, driven by a favorable sales mix and robust demand.

API Business Growth

The API business, with its three decades of steroid chemistry depth and regulated market presence, saw an EBITDA growth of 9%, reaching Rs. 65.8 crore. The gross margins remained upwards of 60%, and EBITDA margins were steady at around 30%. This growth is expected to further accelerate in subsequent quarters as new capacities come online.

Consolidated Performance

Consolidated revenues for the quarter stood at Rs. 218.2 crore, up from Rs. 203.2 crore in the same period last year. Despite a drag from expenses related to new businesses not yet generating revenues, the company remains optimistic about revenue generation from these new ventures in the next 6-12 months. Consolidated EBITDA was Rs. 45.2 crore, down from Rs. 58.0 crore due to higher operating expenses.

Key Operational Highlights

Symbiotec Pharmalab Limited has made significant strides in its regulatory audits, successfully completing four major audits including EUGMP and USFDA audits. The company has also signed a licensing agreement for the distribution of two DCV products in the US and filed its first ANDA for a DCV product in September 2026. Additionally, the company has secured long-term agreements with customers for its biotech CDMO services, further solidifying its position in the market.

As Symbiotec Pharmalab Limited continues to invest in new revenue-generating businesses, the company expects to see a positive impact on its consolidated performance in the coming quarters. With a total gross capex of approximately Rs. 1,666 crore planned by the end of FY27, the company is well-positioned for sustained growth and innovation in the pharmaceutical and biotechnology sectors.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited. Here’s a quick read on where the business and the stock stand today.

Symbol SYMBIOTEC not found in TradeAlone database.